

Clinical Trial for Acute Gout Flare

In this study, we are testing a potential new drug, called ABP-745, for the treatment of acute gout flares.

ABP-745 is designed to reduce pain and inflammation during an acute gout flare. The purpose of this study is to evaluate the safety and effectiveness of this medication.

Participants will randomly be assigned to either receive the investigational treatment, ABP-745, another medication that is currently available to treat gout flares, or a placebo.



What does the study involve?

This trial will run for approximately 7 months and will involve 4 visits to Genesis Research Services in Broadmeadow, in addition to monthly telehealth visits.

Participants will be compensated for their travel and time.



To be eligible, you must be:

- Between 18 - 70 years of age
- Have a medical history or current findings consistent with diagnosis of gouty arthritis
- Have had at least 2 or more gout flares within the past 12 months
- Not be pregnant or breastfeeding

For further information contact Genesis Research Services.



239 - 245 Denison Street
BROADMEADOW

**This study has been approved by St Vincent's
Human Research Ethics Committee.
V1.0 18NOV2025**



02 4985 1860



www.genesisresearchservices.com



reception@genesisresearchservices.com